Health

AstraZeneca heart drug Brilinta may find sailing tough

AstraZeneca heart drug Brilinta may find sailing tough

AstraZeneca heart drug Brilinta may find sailing tough

Many people will not believe this study as it is funded by the company. But other studies are going to throw more light on the genuineness of the claim. AstraZeneca has claimed that its drug Brilinta is very effective in treating long-Term DAPT.

AstraZeneca’s Brilinta is actually the most recent anti-clotting drug from the phama giant. A study conducted by the phama major has claimed that long-term use of the drug not just cuts possibility of heart attacks in heart attack survivors it also brings down the risk factor of stroke or heart-related death.

Though the latest study will be taken with a pinch of salt by the experts across the world as it was funded by AstraZeneca itself, nonetheless from the face value it looks very reliable.

Heart-attackDr. Marc Sabatine, a renowned cardiologist who is associated with Brigham and Women’s Hospital and Harvard Medical School in Boston actually led the study. Researchers tracked outcomes for 21,162 myocardial infarction patients across 31 countries with all of them having survived a heart attack in the previous one to three years.

The same group of people are said to be also suffering from either diabetes or older age thereby putting them at a greater risk for another heart attack and were taking aspirin as a preventive measure. Researchers claim that in the course of the study, patients were randomly given a twice-daily dose of either 90 milligrams (mg) of Brilinta (ticagrelor), 60 mg of the drug, or an inactive placebo. All of them continued to take the low-dose aspirin, ranging from 75 mg to 150 mg.

It is needless to say that researchers were very impressed with the findings of the study. Over an average follow-up of about 33 months, the researchers found that risk of heart attack, stroke and heart-related death was 15 per cent lower among those who took the 90-mg dose of Brilinta and 16 per cent lower among those who took the 60-mg dose of the drug, compared with those who took the placebo.

While talking about the development, a very excited Dr Sabatine said that notwithstanding the fact that both ticagrelor doses reduced ischemic events and cardiovascular death compared with placebo, the better choice was the 60-mg dose as it was better tolerated and the bleeding rate was less with it. “The benefit we saw [from Brilinta] was remarkably consistent across the individual components of [heart health events] and in all the major subgroups of patients,” he went on to add.

More in Health